

1 Reconstructing the household transmission of influenza in the
2 suburbs of Tokyo based on clinical cases

3

4 Masaya M. Saito^{1,2}, Nobuo Hirotsu³, Hiroka Hamada², Mio Takei², Keisuke Honda², Takamichi Baba⁴,
5 Takahiro Hasegawa⁴, Yoshitake Kitanishi⁴

6

7 ¹ University of Nagasaki Siebold, Nagasaki, Japan

8 ² The Institute of Statistical Mathematics, Tokyo, Japan

9 ³ Hirotsu Clinic, Kawasaki, Japan

10 ⁴ Shionogi & Co., Ltd., Osaka, Japan

11

12

13

14

15

16

17

18

19

20

21

22 **Abstract**

23 **Background**

24 Influenza is a public health issue that needs to be addressed strategically and assessment of detailed
25 infectious profiles is important for that. Household transmission data have played a key role for
26 estimating these profiles. From one clinic's influenza diagnostic and questionnaire-based data, we
27 aimed to estimate the detailed infectious period (incubation, symptomatic and infective, and extended
28 infective after recovery) and secondary attack ratio (SAR) for each household size of influenza by
29 using modified Cauchemez-type model.

30 **Results**

31 The data source was derived from enrolled patients with confirmed influenza who were treated at the
32 Hirotsu Clinic (Kawasaki, Japan) with a neuraminidase inhibitor (NAI) during the 6 Northern
33 Hemisphere influenza seasons between 2010 and 2016. A total of 2,342 outpatients representing 1,807
34 households were included. For influenza type A, average incubation period and its 95% probability
35 interval was 1.43 (0.03-5.32) days. Estimated average symptomatic and infective period was 1.76
36 (0.33-4.62) days and point estimated extended infective period after recovery was 0.25 days. Estimated
37 SAR elevated from 20% to 32% as household size increases from 3 to 5. For influenza type B, average
38 incubation period, average symptomatic and infective period, and extended infective period were
39 estimated 1.66 (0.21-4.61) days, 2.62 (0.54-5.75) days and 1.00 days, respectively. SAR was increased
40 12% to 21% as household size increases from 3 to 5.

41 **Conclusion**

42 All estimated periods of influenza type B were longer than those of influenza type A. On the other
43 hands, SAR of type B was less than that of type A. These results may reflect Japanese demographics
44 and treatment policy. It is useful to understand the infectious profiles of influenza for examining public
45 health measures.

46

47 **Keywords**

48 Influenza, Household transmission, Mathematical model, Stochastic simulation, Infectious period,

49 Secondary attack ratio

50

51

52

53 **Background**

54 Simulation-based studies [1, 2] have been effectively used to assess the burden of influenza on society
55 and the reaction for public health, as well as to help understand the dynamical nature of an epidemic
56 [3]. The household is considered a particularly useful artificial experimental environment in which all
57 members of the family experience intense contact [4, 5]. Accordingly, household data have played a
58 key role in solving estimation problems and have received particular attention in influenza infection.
59 In many of these studies, a Reed & Frost-type model was used to estimate the probability that one
60 susceptible subject will experience at least one contact with one infected household subject per unit
61 time [6, 7] using a chain binomial model. In this type of model, the parameters are essentially estimated
62 based on the number of infected subjects at each point in time. As an alternative, Longini et al. [8]
63 proposed a constructive way to estimate the probability of being infected by an infective household
64 member or community from the final numbers at the end of the epidemic. In 2004, Cauchemez et al.
65 [4] applied a new methodology to estimate the force of infection and the distribution of the infectious
66 period simultaneously using a Bayesian Markov chain Monte Carlo (MCMC) approach. In this
67 research, the data from Carrat et al. [9], which included the start and end time of illness for 946
68 households, were used as characteristic data. As a result, the authors were able to provide detailed
69 information on infection duration. It is this method that serves as the focus of the present paper.

70 Although the infective period is one of the most clinically important parameters to describe natural
71 history, it alone is not enough to describe influenza epidemics. There have been numerous attempts to
72 identify other parameters, both in Japan and elsewhere. Frequency of social contacts and the secondary
73 attack ratio (SAR), which is the probability of any member (of $n - 1$) being infected by the primary
74 source, in household contacts are also essential factors for describing epidemics, in addition to the
75 infectious and latent periods. Wallinga et al. [10] quantified the concept of social contacts in an age-
76 specific contact matrix, which was then applied by Mossong et al. [11] in an investigation in Europe.
77 Carcione et al. [12] estimated the SAR in households during the first circulation of the pandemic
78 influenza A(H1N1) 2009. In Japan, Uchida et al. [13, 14, 15] conducted questionnaire-based studies

79 of school outbreaks. Takeuchi et al. [16] and Ibuka et al. [17]**Error! Reference source not found.**]
80 investigated social contacts in a village in Miyazaki prefecture and among age-stratified responders
81 recruited online, respectively. Nishiura & Oshitani [5] estimated the SAR in households for the
82 pandemic influenza A(H1N1) 2009.

83 For a longitudinal study of household transmission, a single-center, prospective, observational study
84 (UMIN - CTR: UMIN000024650) at the Hirotsu Clinic in Kawasaki City, a major city in the greater
85 Tokyo Area, enrolled 2,342 Hirotsu Clinic outpatients and 1,807 households with confirmed influenza
86 during six influenza seasons (2010–2016). In addition to the diagnostic records of individual patients,
87 the accumulated dataset includes the relationships between family members obtained from responses
88 to a questionnaire administered to study participants. These records serve as the basis for the current
89 study.

90 Given the underlying information available in the diagnostic records of the Hirotsu Clinic, we
91 sought to estimate the latent and infectious periods and to reconstruct household transmission in a pair
92 of simulations. The latent period of influenza is hardly identifiable via routinely corrected epidemic
93 data except when a small outbreak occurs, one induced by clearly identified primary cases [6].
94 Moreover, asymptomatic agents may have a non-negligible influence on the epidemic [18, 19].

95 We propose a new household transmission model using a modified Cauchemez-type approach and
96 after conducting two simulation trials to produce a detailed infection profile, we explore the
97 information extracted from the Hirotsu Clinic's influenza diagnosis records. In the first step, estimates
98 of infectious duration are produced by combining the available records and the simulation model. The
99 second step involves a simulation of inter-household transmission assuming a particular force of
100 infection between households and calibrates the assumed value so that the number of simulated
101 infected households for each household size agrees with the reality represented in the data. It is
102 expected that the new and more detailed infectious profile developed here for influenza will contribute
103 to public health globally.

104 The remainder of the paper is organized as follows: In the “Methods” section, the dataset is
105 introduced and the methods applied to the dataset are described mathematically. In the “Results”

106 section, parameter estimates related to the natural history of influenza are presented. Then, in the
107 “Discussion” section, we summarize the outcomes of our trials and discuss the study’s strengths and
108 limitations. Finally, we state conclusion remark and future direction in the “Conclusion” section.

109

110 **Methods**

111 **Data source**

112 The data source was derived from enrolled patients with confirmed influenza who were treated at the
113 Hirotsu Clinic (Kawasaki, Japan) with a neuraminidase inhibitor (NAI) during the 6 Northern
114 Hemisphere influenza seasons between 2010 and 2016. A total of 2,342 outpatients representing 1,807
115 households (Table 1) were included. Patients of any age who were diagnosed with influenza A or B
116 using rapid influenza diagnostic tests (RIDTs) were eligible. ImmunoAce® Flu (Tauns Laboratories,
117 Inc., Shizuoka, Japan) was used for the differential diagnosis of influenza A and B. In order to share
118 the data among members of the research team, the original Hirotsu Clinic data were first anonymized
119 by keeping only assigned identifiers, along with the times of infection-related events and the
120 relationship between identifiers in order to reconstruct households. This anonymization did not affect
121 the analysis. The infection events consisted of the onset (based on questionnaire responses), diagnosis
122 at the clinic, and recovery (occasionally N/A was entered to indicate the disappearance of
123 constitutional symptoms, specifically antipyresis $< 37.5^{\circ}\text{C}$). The dosage and administration of the
124 NAIs were as per the package insert for each product. Secondary infection patients were defined as
125 household members who were diagnosed with the same influenza type as the index patient within 8
126 days after the onset of symptoms in the index patient. It is expected that secondary patients had
127 simultaneous infection with the index patient and secondary infection from the index patient. Figure
128 1 shows that the number of secondary patients was monotonically decreased to 0.5 day in influenza
129 type A and to 1.25 day in influenza type B. It may show that simultaneous infection with the index
130 patient have occurred.

131

132 **Transmission model in a household**

133 Cauchemez et al. [4] conducted a longitudinal investigation of 334 households over a 15-day period
134 and applied their novel household transmission model to estimate parameters describing the natural
135 history of influenza infection. The approach we propose is similar to this in concept. In the model, the
136 time variation of the infectivity attributed to an individual is modeled as a piecewise constant function
137 (Figure 2) that includes four period parameters: asymptomatic and non-infective a , asymptomatic and
138 infective b , symptomatic and infective d , and extended infective after recovery e . By definition,
139 infectivity sustains for period $b + d + e$. Period d was observed from the data; period $b + e$, on the
140 other hand, was estimated via maximum likelihood estimation. Because the individual values of b and
141 e could not be broken out from the combined $b + e$ value, we set $b = 0$ only for conceptual completeness.

142 We employ a parametric model (which will be explained in the next subsection) to describe a and
143 d as random variables and obtain their point estimates via maximum likelihood estimation. The
144 subscripted version (e.g., a_i for a) denotes the values for an individual i . We assume that a given
145 individual may be infected per unit time according to the probability of the sum of the infectivity
146 attributed to the rest of the family members. Specifically, if family member i acquires infectivity at
147 time $t_i - b_i$ (t_i is the illness onset informed by the data) and loses it at $t'_i + e_i$ (optionally informed by
148 the data), then the infection probability per unit time (*i.e.*, the force of infection, FOI) that member j
149 is infected at time t is given by

$$150 \quad \lambda_j(t) = \frac{\lambda_0}{(n-1)^\alpha} \sum_{i \neq j} \mathbb{1}(t_i - b_i \leq t \leq t'_i + e_i), \quad (1)$$

151 where n is the number of members in the household (*i.e.*, the household size), λ_0 is a constant
152 controlling the FOI, and $\mathbb{1}(\cdot)$ is an indicator function: $\mathbb{1}$ (True) = 1 and $\mathbb{1}$ (False) = 0. We
153 introduce the division factor for scaling in a similar manner to Ferguson's simulation study [1].
154 Division by the number of other family members (the case of $\alpha = 1$) assumes that infective contacts
155 occur in an exclusive time-sharing manner; the absence of the division ($\alpha = 0$) implies that the FOIs
156 exert influence equally on the population of concern, irrespective of family size. The former setting is
157 appropriate for diseases that require close contact for infection, including influenza, while the latter

158 well matches, for example, diseases where the infection is induced by polluted agents [20]. However,
159 as we will see, because the SAR is non-negligibly large in large families, setting $\alpha = 1$ appears to
160 over-reduce the FOI: an infective agent may have a conversation with two or more family members.
161 For this reason, we introduced an empirically determined power for scaling.

162

163 Estimation of parameters

164 We employ a rather descriptive statistical approach to estimating a , d , and e . Setting $b = 0$, the
165 symptomatic period $d^{(h,i)}$ of the i -th infected member in household h is informed by data as $t'^{(i)} -$
166 $t^{(i)}$; summing such realizations over all households and members therein, we have the empirical
167 distribution (*i.e.*, histogram) of period d , along with its mean $E[d]$. Similarly in principle, collecting
168 the serial interval instance $t_{\text{int}}^{(h)} := t^{(h,2)} - t^{(h,1)}$ over households h , we have the empirical
169 distribution for t_{int} . However, as is mentioned in Data source subsection, two infected family
170 members occasionally appear almost simultaneously, and these should be discarded from the
171 construction of the serial interval distribution. Figure 1 shows a part of histograms of the crude
172 distribution of t_{int} for influenza A and B, respectively. For influenza B, there is a downward trend
173 up to 1.25 days, followed by an upward trend as a part of bell-shaped distribution (see the entire
174 histogram is shown Figure 3b). We consider this downward trend is mainly attributed to
175 simultaneous infections, in particular t_{int} close to zero. Considering this trend is almost linear, we
176 assumed that the count between t_{int} and $t_{\text{int}} + \Delta t$ is attributed to true household transmission in
177 probability $\propto t_{\text{int}} \Delta t$ and discarded stochastically the data of $t_{\text{int}} < 1.25$ days accordingly. The
178 same procedure is applied to influenza A with a different cut-off, $t_{\text{int}} < 0.5$, though the downward
179 trend is not so clear as influenza B. After such adjustments, the “observed” serial interval t_{int} can
180 be modeled as the summation of the interval τ_{int} between the infection times of the primary and
181 secondary infections (*i.e.*, the “intrinsic” serial interval) and the incubation period a of the secondary
182 subject. For ease of computation of the a distribution, we introduce two simplifications. First, the
183 interval of the two cases is assumed to follow a uniform distribution truncated at the mean infective

184 period τ_{ifv} : $p(\tau_{\text{int}}) = \mathbb{1}(0 \leq \tau_{\text{int}} \leq \tau_{\text{ifv}})/\tau_{\text{ifv}}$. Second, the incubation period follows a gamma
 185 distribution: $a \sim \text{Gam}(\text{shape} = k_a, \text{scale} = \theta_a)$. The distribution form of t_{int} is then written as

$$186 \quad p(t_{\text{int}} | k_a, \theta_a, \tau_{\text{ifv}}) = \frac{d}{dt_{\text{int}}} \int_0^{\min(t_{\text{int}}, \tau_{\text{ifv}})} \frac{1}{\tau_{\text{ifv}}} \int_{\tau_{\text{int}}}^{t_{\text{int}}} \text{Gam}(t'_{\text{int}} - \tau_{\text{int}} | k_a, \theta_a) dt'_{\text{int}} d\tau_{\text{int}} \\ 187 \quad = \frac{1}{\tau_{\text{ifv}}} \int_0^{\min(t_{\text{int}}, \tau_{\text{ifv}})} \text{Gam}(t_{\text{int}} - \tau | k_a, \theta_a) d\tau.$$

188 By maximizing the likelihood $\prod_h p(t_{\text{int}} = t_{\text{int}}^{(h)} | k_a, \theta_a, \tau_{\text{ifv}})$, we have the distribution of
 189 incubation period a . Technically, the simultaneous optimization of $(k_a, \theta_a, \tau_{\text{ifv}})$ is sensitive to the
 190 initial conditions. Hence, given τ_{ifv} in a certain range, we optimize for (k_a, θ_a) . Since a point
 191 estimate of the infective period τ_{ifv} can be equated to $E[d + e]$, $\tau_{\text{ifv}} - E[d]$ serves as a point
 192 estimate of e . Scaling power α is determined as follows. The SAR is $1 - e^{-\lambda\tau_{\text{ifv}}} \approx \lambda\tau_{\text{ifv}}$ with $\lambda =$
 193 $(n - 1) \cdot \lambda_0/(n - 1)^\alpha$, from Eq. (1). Our dataset allows us to compute the
 194 SAR for household sizes $n = 3, 4$, and 5 . Therefore, the value of α with $\lambda_0\tau_{\text{ifv}}$ is determined by the
 195 regression

$$196 \quad \log \text{SAR}_n = \log \lambda_0 \tau_{\text{ifv}} + (1 - \alpha) \log(n - 1).$$

197 The value of λ_0 is determined as an MLE via a comparison of the number of secondary cases in the
 198 data and in the simulation. Suppose that i secondary cases appear in a simulated household of size n
 199 with probability $p_{i/n}$ and that $(p_{i/n})_{i=0}^{n-1}$ is obtained through multiple simulation runs with different
 200 seeds. Then the likelihood for the comparison is $L(\lambda_0) = \prod_{n=3,4,5} \prod_{i=0}^{n-1} (p_{i/n})^{m_{i/n}}$, given $m_{i/n}$ real
 201 households yielded i secondary cases. In other words, λ_0 is chosen so that the KL divergence is
 202 minimized.

203

204 Results

205 Estimation of duration parameters

206 To estimate the duration parameters, we first summarized the dataset in the form of histograms for the
 207 symptomatic period and the serial interval. The dataset histograms for influenza A, along with the

related estimation results, are shown in Figure 3a. We identified 1,389 cases in which the patient exhibited symptoms and 290 transmissions from the primary to the secondary subject. The symptomatic period distribution is well approximated by a gamma distribution with shape = 2.97 and scale = 0.59 days; that is, period d is 1.76 days on average, with a 95% probability interval (hereafter 95% I) of 0.33-4.62. The point estimate of the infective period as the MLE is 2.01 (left-panel in Figure 3a). The difference between the infective and symptomatic periods is the extended infective period after recovery, e ; here, $e = 2.01 - 1.76 = 0.25$ days. The incubation period is extracted as a gamma distribution with shape = 0.99 and scale = 1.46 days (mean: 1.43 days; 95% I: 0.03-5.32 days).

The results for influenza B are shown in Figure 3b. For the analysis here, we identified 760 cases where the patient exhibited symptoms and 135 transmissions from the primary to the secondary subject. A gamma distribution with shape = 3.05 and scale = 0.86 days (mean: 2.62 days; 95% I: 0.54-5.75 days) was fitted to the symptomatic period data; notably, the period here is longer than in the case of influenza A. The serial interval was also longer and cut off at approximately 6 days, while the infective period was estimated be 3.62 days, which yields the incubation period of 1.66 days (95% I: 0.21-4.61 days), as well as a relatively long extended infective period after recovery, $e = 3.62 - 2.62 = 1.00$ days.

223

224 Estimation of FOI

We then produced a point estimate of the FOI coefficient λ_0 after fixing scaling power α . In the case of influenza A, the SAR elevated from 20% to 32% as household size increases from 3 to 5, for which $\alpha = 0.32$ is optimal. This is a much smaller value than that used in a previous study, where Ferguson et al. [1], who carried out agent simulations and employed a Cauchemez-type model as an internal process, used $\alpha = 0.8$. With $\alpha = 0.32$ and an infective period of 3.73 days. We ran 1,024 simulations to obtain the ML estimate of λ_0 . The likelihood as a function of λ_0 is shown in Figure 4a; the optimal value was found to be $\lambda_0 = 0.065$. The corresponding SAR distribution is shown in Figure 5a. As shown, the simulated distribution well reproduces the data.

The same procedure was applied to influenza B. Compared to type A, type B exhibited a smaller SAR (range: 12%-21%) and a much longer infective period (5.73 days). The resulting estimates are

235 also different: $\alpha = 0.17$ and $\lambda_0 = 0.015$. The likelihood function is shown in Figure 4b. The SAR
236 distribution in Figure 5b is similarly reproduced, and two or more secondary cases appear less
237 frequently than for type A.

238

239 Discussion

240 We estimated parameters to describe an influenza natural history, the incubation and infective periods,
241 and the FOI coefficient, using both diagnostic and questionnaire-based data obtained in a clinic located
242 in the suburbs of Tokyo. While the study produced several useful insights, it is not without limitations.
243 Although the estimated incubation period is rather inescapably obscure because it is hidden by the
244 different symptomatic periods for individuals and was reflected in a quite skewed distribution with
245 shape less than unity, it was estimated to be roughly 1.5 day both for type A and B. For the latter, a
246 uniform infective period distribution with bi-level infectivity (non-infective or infective) does not fully
247 capture the nature of the influenza (e.g., virus titer over time). The difference between the infective
248 period and the symptomatic period, for which we produced point estimates, was 0.25 days for
249 influenza type A and 1.00 days for type B. While the estimate for type B would seem to correspond to
250 general medical intuition, the estimate for type A appears excessively short. According to Enforcement
251 Regulations for School Health and Safety Act in Japan [21], patients with influenza virus infection are
252 banned from attending school within 2 days (or 3 days for infant children) after the resolution of fever.
253 These estimates of the mean of the extended infective period after the resolution of fever were lower
254 than 2 or 3 days and corresponded to the description of this enforcement regulation in Japan. Therefore,
255 our constructed models would make sense in this regard. But it should be noted that the choice of cut-
256 off points which splits simultaneous infection from the true household transmission is in fact
257 influential in the estimation and it is rather obscure in type A. The scaling power was estimated to be
258 quite small ($\alpha = 0.2$ to 0.3). A straightforward explanation for this might be that the dataset covered
259 households in which family members tended to spend most of their time with one another. However,
260 two (or more) primary cases introduced almost simultaneously can elevate the apparent SAR in large
261 families. Our analysis assumed that the first reported case infected the second, and so on. The fraction

262 of the ignored tail (> 8 days) should be available to model the probability that multiple members were
263 infected simultaneously, referring to epidemic surveillance in Tokyo. It should also be noted that the
264 SAR may be underestimated due to the basic strategy of early diagnosis followed by early treatment.

265

266 Conclusion

267 All estimated periods of influenza type B were longer than those of influenza type A. On the other
268 hands, SAR of type B was less than that of type A. This study was conducted in Japan; therefore, these
269 results may reflect Japanese demographics and treatment policy. Although it is important to assess
270 these infectious profiles in each country, the number of studies that estimated infectious duration and
271 FOI of influenza in Japan is very limited. It is useful to understand the infectious profiles of influenza
272 for examining public health measures. More research may be performed to improve the accuracy of
273 the results which can potentially be used for better public health.

274

275 Declarations

276 Ethics approval and consent to participate

277 The protocol was approved by the ethics committee of Shionogi & Co., Ltd. Informed consent was
278 not required, because the anonymized data was shared with the Institute of Statistical Mathematics
279 only as required by law, Act on the Protection of Personal Information.

280 Consent for publication

281 Not applicable

282 Availability of data and materials

283 Not applicable

284 Competing interests

285 TB, TH and YK are employees of Shionogi & Co., Ltd. NH has received research funding and has
286 served as a consultant, advisory board member, and/or speaker for Shionogi & Co., Ltd.

287 **Funding**

288 Not applicable

289 **Authors' contributions**

290 All authors participated in the analysis method and interpretation of analysis results, and in the drafting,
291 critical revision, and approval of the final version of the manuscript. NH was responsible for data
292 collection and anonymization. MS and HH conducted the statistical analysis. MT developed a program
293 for anonymization and provide it to NH.

294 **Acknowledgements**

295 Anonymization of the original dataset was carried out at Hirotsu Clinic using a dedicated code
296 provided by Professor Kazuhiro Minami at the Institute of Statistical Mathematics, Japan. We would
297 like to express our deepest gratitude for his contribution.

298

299 **References**

- 300 1. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A,
301 Iamsirithaworn S, Burke DS. Strategies for containing an emerging influenza
302 pandemic in Southeast Asia. *Nature* 2005; 437(7056):209–214.
- 303 2. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W,
304 Cummings DAT, Halloran ME. Containing pandemic influenza at the source.
305 *Science* 2005; 309(5737):1083–1087.
- 306 3. Colizza V, Barrat A, Barthélemy M, Vespignani A. The role of the airline
307 transportation network in the prediction and predictability of global
308 epidemics. *Proc Natl Acad Sci U S A* 2006; 103(7):2015–2020.

- 309 4. Cauchemez S, Carrat F, Viboud C, Valleron AJ, Boëlle PY. A Bayesian
310 MCMC approach to study transmission of influenza: application to household
311 longitudinal data, *Stat Med* 2004; 23(22):3469–3487.
- 312 5. Nishiura H, Oshitani H. Household transmission of influenza (H1N1-2009) in
313 Japan: age-specificity and reduction of household transmission risk by
314 Zanamivir treatment. *J Int Med Res* 2011; 39(2):619–628.
- 315 6. Hirotsu N, Saisho Y, Hasegawa T. The effect of neuraminidase inhibitors on
316 household transmission in Japanese patients with influenza A and B infection:
317 a prospective, observational study. *Influenza Other Respir Viruses* 2019;
318 13(2):123–132.
- 319 7. Abbey H. An examination of the Reed-Frost theory of epidemics. *Hum Biol*
320 1952; 24(3):201–233.
- 321 8. Longini IM, Koopman JS. Household and community transmission
322 parameters from final distributions of infections in households. *Biometrics*
323 1982; 38(1):115–126.
- 324 9. Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Gales CL,
325 Bungener M, Housset B, Nicolas M, Rouzioux C. Influenza burden of illness:
326 estimates from a national prospective survey of household contacts in France.
327 *Arch Intern Med* 2002; 162(16):1842–1848.
- 328 10. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to
329 estimate age-specific transmission parameters for respiratory-spread
330 infectious agents. *Am J Epidemiol* 2006; 164(10):936–944.
- 331 11. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M,
332 Salmaso S, Tomba GS, Wallinga J, Heijne J, Sadkowska-Todys M, Rosinska

- 333 M, Edmunds WJ. Social contacts and mixing patterns relevant to the spread
334 of infectious diseases. *PLoS Med* 2008; 5(3):e74.
- 335 12. Carcione D, Giele CM, Goggin LS, Kwan KS, Smith DW, Dowse GK, Mak
336 DB, Effler P. Secondary attack rate of pandemic influenza A(H1N1) 2009 in
337 western Australian households, 29 May-7 August 2009. *Euro Surveill* 2011;
338 16(3):19765.
- 339 13. Uchida M, Tsukahara T, Kaneko M, Washizuka S, Kawa S. Swine-origin
340 influenza a outbreak 2009 at Shinshu university, Japan. *BMC Public Health*
341 2011; 11:79.
- 342 14. Uchida M, Kaneko M, Hidaka Y, Yamamoto H, Honda T, Takeuchi S, Saito
343 M, Kawa S. Effectiveness of vaccination and wearing masks on seasonal
344 influenza in Matsumoto city, Japan, in 2014/2015 season: an observational
345 study among all elementary schoolchildren. *Prev Med Rep* 2016; 5:86–91.
- 346 15. Uchida M, Takeuchi S, Saito MM, Koyama H. Effects of influenza
347 vaccination on seasonal influenza symptoms: a prospective observational
348 study in elementary schoolchildren in Japan. *Heliyon* 2020; 6(2):e03385.
- 349 16. Takeuchi S, Yamauchi T, Kuroda Y. Increased fertility in an aging society
350 will affect the spread of infectious diseases: a case study in Miyazaki
351 prefecture. *Jpn J Health & Human Ecology* 2014; 80(1):17–22 (in Japanese).
- 352 17. Ibuka Y, Ohkusa Y, Sugawara T, Chapman GB, Yamin D, Atkins KE,
353 Taniguchi K, Okabe N, Galvani AP. Social contacts, vaccination decisions
354 and influenza in Japan. *J Epidemiol Community Health* 2016; 70(2):162–167.

- 355 18. Brauer F. Modeling Influenza: Pandemics and Seasonal Epidemics. In:
- 356 Brauer F, van den Driessche P, Wu J (eds) *Mathematical Epidemiology*.
- 357 *Lecture notes in mathematics, vol 1945.* Springer: Berlin, Heidelberg, 2008.
- 358 19. Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack
- 359 rate of seasonal influenza among unvaccinated individuals: a systematic
- 360 review and meta-analysis. *Vaccine* 2018; 36(23):3199–3207.
- 361 20. Vynnycky E, White RG. *An Introduction to Infectious Disease Modelling*.
- 362 Oxford University Press: New York, 2010.
- 363 21. The Website (in Japanese). (Available at: https://elaws.e-gov.go.jp/search/elawsSearch/elaws_search/lsg0500/detail?lawId=333M50000080018#137) [accessed on June 9, 2020].
- 366

367 **Tables**

368 **Table 1**

369 **Summary of diagnosed influenza cases covered by our questionnaire investigation.**

Year	Type	Cases	Households	Total Cases
1	A	243	189	
	B	104	86	347
2	A	263	204	
	B	222	177	485
3	A	259	189	
	B	11	8	270
4	A	175	147	
	B	289	227	464
5	A	339	249	
	B	18	13	357
6	A	237	168	
	B	182	150	419
		Total	2342	1807

370

371

372 **Figures**

373 **Figure 1.** Histogram of the crude number of secondary cases for each serial interval (the part < 2 days).

374 In both the types, there is a downward trend up to 0.5 days (type A) and 1.25 days (type B), which
375 may be attributed to simultaneous infections outside the household.

376

377 **Figure 2.** Natural history of infective people and the variation of infectivity. In an actual situation, a
378 person may be infected at some unknown point in time (Infection) and the infectivity to other people
379 gradually increases up to its maximum around the time when the illness is well developed and
380 recognized (Illness onset). It then is drained as the process of recovery from infection proceeds, which
381 may be clinically observed by antipyresis (Antipyresis), though weak infectivity may remain. For
382 simplicity, such time variation of infectivity is modeled using a piecewise constant function that takes
383 a non-zero constant value λ_0 only from one point in time (labeled as Infective) to another point near
384 Antipyresis. The modeled infectivity function is temporally controlled by four period parameters: a
385 (asymptomatic and non-infective), b (asymptomatic and infective), d (symptomatic and infective) and
386 e (extended infective after recovery).

387

388 **Figure 3.** Summary of household infection data and estimates of the parameters for influenza types.

389 a. Type A and b. type B (bottom row). The left column shows the histogram of the symptomatic period
390 and its fitting to a gamma distribution. The middle column shows the histogram of the serial interval,
391 its fitting to the distribution constructed as a convoluted gamma distribution (blue curve), and the
392 extracted infective period (annotation) and incubation period (red curve) via the fitting (see methods
393 section for detail). The right column shows the negative likelihood against the assumed infective
394 period.

395

396 **Figure 4.** Likelihood curves for the two influenza types. a. Type A and b. type B are shown with
397 respect to the number of secondary cases in a household as a function of the force of infection (FOI)
398 coefficient λ_0 . The likelihood values are determined by simulation runs with different values of λ_0 and

399 $\Delta\lambda_0 = 0.005$; optimal values of λ_0 are 0.065 for A and 0.015 for B.

400

401 **Figure 5.** Comparison of the number of secondary cases in a household. Households have 3, 4, or 5
402 members in the actual data (white) and the simulation (black) for the two influenza types: a. A and b.
403 B. The simulation run is mainly controlled by the force of infection (FOI) coefficient λ_0 and the
404 household size scaling power a ; their ML estimates are shown.